|
|
||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Laboratory of Innate Immunology, Centre Hospitalier Universitaire de Quebec Research Center (Centre Hospitalier de lUniversité Laval) and Department of Molecular Medicine, Laval University, Quebec, Canada
TLRs are known to be important in innate host defense against a variety of microbial infections. In particular, TLR9 has been associated with immune defense against different foreign organisms by recognition of unmethylated DNA sequences. In this report, we provide evidence that leukotriene B4 (LTB4) has the capacity to modulate TLR9 expression on human neutrophils. The effect of LTB4 was found to be specific, because related leukotrienes such as LTC4 and LTD4 or neutrophil agonists IL-8 and C5a failed to modulate TLR9 expression in neutrophils. Using fluorochrome-tagged CpG DNA, we observed that LTB4 treatment also increased TLR9 ligand binding in neutrophils. Moreover, LTB4 stimulation potentiates CpG-mediated signaling via an endosome-independent mechanism in human neutrophils, leading to enhanced secretion of proinflammatory cytokines. The increase in cytokine secretion by LTB4 following CpG stimulation of neutrophils was associated with the activation of TGF-β-activated kinase (TAK-1) as well as p38 and c-Jun (JNK) kinases. In contrast, in PBMC LTB4 leads to an increase in cytokine secretion following CpG stimulation but via a MyD88- and endosome-dependent mechanism. As observed in neutrophils, PBMC stimulation with LTB4 in the presence of CpG also results in enhanced TAK-1, p38, and JNK phosphorylation/activation. These data provide new evidence underlying the immunomodulatory properties of LTB4 leading to antimicrobial defense.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
1 This project was supported by a grant from The Canadian Institutes of Health Research (to J.G.). E.G. is a recipient of a scholarship from Fondation Dr. Georges Phénix.
J.G. designed the research, E.G. performed the research, and J.G. and E.G. analyzed the data and wrote the manuscript.
2 Address correspondence and reprint requests to Dr. Jean Gosselin, Laboratory of Innate Immunology, Centre Hospitalier Universitaire de Québec Research Center Research Center (Centre Hospitalier de lUniversité Laval), 2705 Boulevard Laurier, Room T 1–49, Québec, Québec, Canada G1V 4G2. E-mail address: jean.gosselin{at}crchul.ulaval.ca
3 Abbreviations used in this paper: ODN, oligodeoxynucleotide; DA, DNA-dependent activator of IFN regulatory factors; LT, leukotriene; TAK-1, TGF-β-activated kinase-1; TRIF, Toll/IL-1R domain-containing adapter inducing IFN-β; WT, wild type; PBMC, peripheral blood mononuclear cell.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |